All lobbying filings

MARSHALL & POPP, LLC

Lobbying for GENENTECH, INC. · Biotechnology company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 4

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
SCONRES 7
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…

Lobbying activity 4

Pharmacy

Issues related to prescription drug value, including H.R.1 - One Big Beautiful Bill Act, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R.1 - One Big Beautiful Bill Act. Issues related to the 340B program.

Issues related to tariff and trade policy.

Trade (domestic/foreign)

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.